



## LABORATORIOS FARMACÉUTICOS ROVI, S.A

Julián Camarillo, 35  
Teléfono 91 375 62 30  
28037 MADRID

Fax. 91 304 78 81  
Dir. Teleg.: ROBRISA  
Apartado de Correos 35.027  
E-mail: rovi@rovi.es  
Http://www.rovi.es

### STEM CELL POLICY

The object of this document is to describe the Stem Cell Policy of Rovi Group as a basis of our commitment to the responsible use of stem cell in research in case of needed.

There is growing awareness of the potential health and social benefits of using stem cells as a treatment for diseases or even as a cure of them. These stem cells divide in daughter cells that can develop into specialized cells (bone, blood, neuronal cells...) capable of regenerating damaged tissue.

On the other hand, ROVI Group acknowledges the challenge of conducting these cells into the expected specialized cells and the risk and controversies associated with the use of this type of emergency technologies.

ROVI Group has a long history of developing new drugs (it has a wide R&D area) and recognizes the high potential of stem cell research, but up to date it has not used this kind of genetic technology in its studies.

However, ROVI Group is committed to support further research or engage with stakeholders on emerging technologies that meet the highest ethical standards whether is a high benefit to patients and the treatment has not otherwise been achieved.

In this case, Rovi Group is committed to following the Guidelines for Human Stem Cell research stipulated by National Institutes of Health in 2009 supporting and conducting responsible, scientifically worthy human stem cell research, including human embryonic stem cell (hESC) research to the extent permitted by law.

Rovi Group excludes research for the cloning of human being.

In this line, Rovi Group commits to avoid the most controversial practices related to these technologies being ethically responsible, scientifically worthy, and conducted in accordance with applicable law.

APPROVED BY

Juan López-Belmonte Encina

C.E.O